NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CING Stock Alerts $0.88 +0.04 (+4.76%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.84▼$0.9350-Day Range$0.79▼$1.3552-Week Range$0.75▼$23.40Volume8,653 shsAverage Volume306,203 shsMarket Capitalization$4.41 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cingulate alerts: Email Address Cingulate MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside809.0% Upside$8.00 Price TargetShort InterestHealthy0.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 3 Articles This WeekInsider TradingAcquiring Shares$1,490 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 stars 3.2 Analyst's Opinion Consensus RatingCingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCingulate has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.58% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently decreased by 66.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CING. Previous Next 1.3 News and Social Media Coverage News SentimentCingulate has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cingulate this week, compared to 3 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,490.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.43% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cingulate is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cingulate is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cingulate Stock (NASDAQ:CING)Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More CING Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CING Stock News HeadlinesApril 24, 2024 | msn.comStress activates brain regions linked to alcohol use disorder differently for women than men, finds studyApril 23, 2024 | americanbankingnews.comCingulate (NASDAQ:CING) Trading 0.8% Higher April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 18, 2024 | msn.comResearchers identify 45 distinct brain connectivity alterations linked to anorexia nervosaApril 16, 2024 | finance.yahoo.comCingulate to Participate in Planet MicroCap Showcase: Vegas 2024April 1, 2024 | bizjournals.comCingulate CEO talks about the pharmaceutical company's road ahead after tough 2023April 1, 2024 | globenewswire.comCingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateMarch 28, 2024 | yahoo.com5 Easy Secrets of Super Agers That Can Help You Live a Long and Happy LifeApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 20, 2024 | bizjournals.comCingulate can add $3.5M to latest stock offering as it navigates FDA drug approvalMarch 19, 2024 | globenewswire.comCingulate to Participate in Benzinga All Live Access EventMarch 13, 2024 | msn.comADHD linked to unusual brain connectivity patterns in large-scale neuroimaging studyMarch 13, 2024 | msn.comBreakups Can Actually Change Your Brain Chemistry—Here's HowMarch 12, 2024 | nz.news.yahoo.comWhy you can't focus and what science says can helpMarch 12, 2024 | sg.news.yahoo.comHere's why you can't focus - and science-backed ways to help youMarch 11, 2024 | msn.comSelf-hypnosis is soaring in popularity RN - I tried it after hearing that it could boost your mood and mental health from homeMarch 6, 2024 | globenewswire.comCingulate to Attend DCAT Week 2024 in New York CityFebruary 28, 2024 | bizjournals.comCingulate regains compliance with Nasdaq, maintaining key capital sourceFebruary 25, 2024 | msn.comUsing deep brain stimulation to map dysfunctional brain circuits linked to four disordersFebruary 22, 2024 | foxnews.comNew York woman reports improved mental health after undergoing brain electrode therapyFebruary 22, 2024 | msn.comBrain Pacemaker? New Stimulation Device Tested to Treat Depression Shows Promising ResultsFebruary 22, 2024 | msn.comResearchers use deep brain stimulation to map therapeutic targets for four brain disordersFebruary 22, 2024 | msn.comWoman Says Experimental Brain Implant Helped Her Lifelong Depression: 'Continuous Prozac'February 21, 2024 | dailymail.co.ukA pacemaker for the brain helped a woman with crippling depression. It may soon be available to moreFebruary 18, 2024 | msn.comAdditional study shows promise for low-intensity ultrasound as a non-invasive approach to alleviate painFebruary 14, 2024 | bizjournals.comCingulate adds three new members to board, following exits in DecemberFebruary 14, 2024 | msn.comMaltreatment linked to altered brain structure and spontaneous thought patterns in children, study findsSee More Headlines Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+809.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($32.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-432.81% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.88) per share Price / Book-0.15Miscellaneous Outstanding Shares5,010,000Free Float3,085,000Market Cap$4.41 million OptionableNot Optionable Beta-0.95 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Shane J. Schaffer Pharm.D. (Age 48)PharmD, CEO, Principal Financial Officer & Chairman of the Board Comp: $491.96kDr. Laurie A. Myers M.B.A. (Age 66)Ph.D., Executive VP & COO Comp: $415.17kDr. Matthew N. Brams M.D. (Age 59)Executive VP & Chief Medical Officer Comp: $244.79kMs. Jennifer L. Callahan CPA (Age 53)CFO, Senior VP & Corporate Controller Dr. Raul R. Silva M.D. (Age 65)Executive VP & Chief Science Officer Thomas DaltonHead of Investor & Public RelationsMore ExecutivesKey CompetitorsLipella PharmaceuticalsNASDAQ:LIPOGenprexNASDAQ:GNPXTharimmuneNASDAQ:THARZyVersa TherapeuticsNASDAQ:ZVSASeelos TherapeuticsNASDAQ:SEELView All CompetitorsInsidersJennifer L CallahanBought 55 shares on 3/15/2024Total: $1,490.50 ($27.10/share)Jennifer L CallahanBought 250 shares on 9/15/2023Total: $3,350.00 ($13.40/share)Peter J WerthBought 91,157 shares on 8/11/2023Total: $1.00 M ($11.00/share)Jennifer L CallahanBought 100 shares on 5/15/2023Total: $2,020.00 ($20.20/share)Jennifer L CallahanBought 200 shares on 5/12/2023Total: $4,320.00 ($21.60/share)View All Insider Transactions CING Stock Analysis - Frequently Asked Questions Should I buy or sell Cingulate stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares. View CING analyst ratings or view top-rated stocks. What is Cingulate's stock price target for 2024? 3 brokerages have issued twelve-month price objectives for Cingulate's shares. Their CING share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 809.0% from the stock's current price. View analysts price targets for CING or view top-rated stocks among Wall Street analysts. How have CING shares performed in 2024? Cingulate's stock was trading at $7.65 at the beginning of the year. Since then, CING shares have decreased by 88.5% and is now trading at $0.8801. View the best growth stocks for 2024 here. Are investors shorting Cingulate? Cingulate saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 13,900 shares, a decline of 66.5% from the March 31st total of 41,500 shares. Based on an average daily volume of 308,600 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.6% of the company's stock are short sold. View Cingulate's Short Interest. When is Cingulate's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CING earnings forecast. When did Cingulate's stock split? Cingulate's stock reverse split on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CING) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
